ML18156A444
| ML18156A444 | |
| Person / Time | |
|---|---|
| Site: | 11006300 |
| Issue date: | 06/04/2018 |
| From: | Peter Habighorst NRC/OIP |
| To: | Rothwell P Vertex Pharmaceuticals Incorporated |
| Savoy J | |
| References | |
| Download: ML18156A444 (2) | |
Text
EXPORT LICENSE NRC FORM 250 (10-07)
NRC LICENSE NO.: XMAT444 UNITED STATES OF AMERICA Page 1 of 2 Nuclear Regulatory Commission NRC DOCKET NO.: 11006300 Washington, D.C. 20555 LICENSE EXPIRES June 30, 2023 Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the U.S. Nuclear Regulatory Commission (NRC)issued pursuant thereto, and In reliance on statements and representations heretofore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.
LICENSEE ULTIMATE CONSIGNEE(S)IN FOREIGN COUNTRY(IES)
Vertex Pharmaceuticals Incorporated See Page 2 50 Northern Avenue Boston, MA 02210 Attn: Paula Rothwell INTERMEDIATE CONSIGNEE(S)IN FOREIGN COUNTRY(IES) OTHER PARTY(IES)TO EXPORT NONE See Page 2 APPLICANT'S REFERENCE NO.: Appl. date 1/30/18 ULTIMATE DESTINATION(S): Spain QUANTITY(IES) DESCRIPTION OF MATERIAL(S)OR FACILITY(IES) 5,000 kilograms Deuterium in the form of deuterium gas, deuterium oxide, and deuterium compounds.
THIS LICENSER I^ALID UNLESS SIGNED BELOW Neither this license nor any right under this license shall be BY AUTI^^ED NRC REPRESENTATIVE assigned or otherwise transferred In violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974. SIGNATURE: i This license is subject to the right of recapture or control by NAME AND TITLE Peter J. HabighorstrActing Deputy Director Section 108 of the Atomic Energy Act of 1954, as amended, and to Office of International Programs all of the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of the NRC. DATE OF ISSUANCE: 0h(O4l EXPORT LICENSE
XMAT444 Page 2 of 2 ULTIMATE CONSIGNEEfS)IN FOREIGN COUNTRYflES):
- 1. Esteve Quimica, S.A.
Poligon Industral, s/n 17460 Celra (Girona)
Spain (Manufacture active pharmaceutical ingredients for non-nuclear end use in clinical trials for the treatment of cystic fibrosis)
- 2. Esteve Quimica, S.A.
Ctra. Del Vendrell a St. Jaume dels Domenys, km 5 43711 Banyeres del Penedes (Tarragona)
Spain (Manufacture active pharmaceutical ingredients for non-nuclear end use in clinical trials for the treatment of cystic fibrosis)
- 3. Esteve Quimica, S.A.
c/Caracas, 17-19 08030 Barcelona Spain (Manufacture active pharmaceutical Ingredients for non-nuclear end use in clinical trials for the treatment of cystic fibrosis)
OTHER U.S. PARTYMESI TO EXPORT:
- 1. Cambridge Isotope Laboratories, Inc.
50 Frontage Road Andover, MA 01810 (Supplier/distributor)
- 2. Aldrich Chemical Co. LLC 6000 North Teutonia Avenue Milwaukee, Wl 53209 (Supplier/distributor)
- 3. Aldrich Chemical Co. LLC 3858 Benner Road Miamisburg, OH 45342 (Supplier/distributor)
- 4. Sigma Aldrich Fine Chemicals(SAFC) 5485 County Road V Sheboygan Falls. Wl 53085 (Supplier/distributor)